

---

---

## HOUSE RESOLUTION

REQUESTING THE DEPARTMENT OF HEALTH TO CONVENE A MEDICINAL  
PSILOCYBIN WORKING GROUP TO EXAMINE THE MEDICINAL AND  
THERAPEUTIC EFFECTS OF PSILOCYBIN AND DEVELOP A LONG-TERM  
STRATEGIC PLAN TO ENSURE THE AVAILABILITY OF MEDICINAL  
PSILOCYBIN OR PSILOCYBIN-BASED PRODUCTS THAT ARE SAFE,  
ACCESSIBLE, AND AFFORDABLE FOR ELIGIBLE ADULT PATIENTS.

1           WHEREAS, mental health conditions are treated in various  
2 ways depending on the condition, and can include medication,  
3 therapy, and psychosocial services; and  
4

5           WHEREAS, these treatments, while effective for certain  
6 conditions and patients, do not treat all mental health  
7 conditions; and  
8

9           WHEREAS, psilocybin occurs naturally in certain species of  
10 mushrooms; and  
11

12           WHEREAS, psilocybin is a natural chemical that can activate  
13 serotonin receptors in the brain; and  
14

15           WHEREAS, studies conducted by nationally and  
16 internationally recognized medical institutions indicate that  
17 psilocybin has shown efficacy, tolerability, and safety in the  
18 treatment of a variety of mental health conditions, including  
19 addiction, depression, anxiety disorders, and end-of-life  
20 psychological distress; and  
21

22           WHEREAS, the United States Food and Drug Administration has  
23 determined that preliminary clinical evidence indicates that  
24 psilocybin may demonstrate substantial improvement over  
25 available therapies for major depressive disorder and severe  
26 treatment-resistant depression and has granted a breakthrough  
27 therapy designation for a treatment that uses psilocybin as a  
28 therapy for major depressive disorder and a breakthrough therapy



1 designation for a treatment that uses psilocybin as a therapy  
2 for severe treatment-resistant depression; and  
3

4 WHEREAS, Hawaii has a shortage of mental health  
5 professionals, and should actively consider novel, innovative,  
6 and safe solutions to treat its citizens; now, therefore,  
7

8 BE IT RESOLVED by the House of Representatives of the  
9 Thirtieth Legislature of the State of Hawaii, Regular Session of  
10 2020, that the Department of Health is requested to convene a  
11 Medicinal Psilocybin Working Group, to be placed in the  
12 Department of Health for administrative purposes; and  
13

14 BE IT FURTHER RESOLVED that the Medicinal Psilocybin  
15 Working Group is requested to examine:  
16

- 17 (1) Federal, state, and local laws, regulations,  
18 administrative rules, and procedures regarding the  
19 medicinal use of psilocybin;  
20
- 21 (2) Available medical, psychological, and scientific  
22 studies, research, and other information relating to  
23 the safety and efficacy of psilocybin in treating  
24 mental health conditions; and  
25
- 26 (3) Requirements, specifications, and guidelines for a  
27 medical professional to prescribe and provide  
28 psilocybin; and  
29

30 BE IT FURTHER RESOLVED that the Medicinal Psilocybin  
31 Working Group is requested to develop a long-term strategic plan  
32 to ensure the availability of medicinal psilocybin or  
33 psilocybin-based products that are safe, accessible, and  
34 affordable for adults twenty-one years of age or older; and  
35

36 BE IT FURTHER RESOLVED that the following individuals, or  
37 their respective designees, are requested to serve as members of  
38 the Medicinal Psilocybin Working Group:



- 1           (1) The Director of Health, who is requested to serve as  
2           chair of the working group;
- 3
- 4           (2) The Attorney General;
- 5
- 6           (3) The Dean of the John A. Burns School of Medicine at  
7           the University of Hawaii at Manoa;
- 8
- 9           (4) The chairs of the Senate and House of Representatives  
10           standing committees whose subject matter purview is  
11           primarily responsible for reviewing legislation  
12           relating to health and to the Judiciary;
- 13
- 14           (5) A physician duly licensed under Chapter 453, Hawaii  
15           Revised Statutes, or advanced practice registered  
16           nurse with the authority to prescribe psychotropic  
17           medication and duly licensed under Chapter 457, Hawaii  
18           Revised Statutes, to be invited by the chair of the  
19           working group;
- 20
- 21           (6) A psychiatrist duly licensed under Chapter 453, Hawaii  
22           Revised Statutes, to be invited by the chair of the  
23           working group;
- 24
- 25           (7) A representative of the Drug Policy Forum of Hawaii,  
26           to be invited by the chair of the working group;
- 27
- 28           (8) A representative of the Clarity Project, to be invited  
29           by the chair of the working group;
- 30
- 31           (9) A representative of the public with  
32           psychedelics-related industry experience, to be  
33           invited by the chair of the working group;
- 34
- 35           (10) A representative of the Hawaii Psychological  
36           Association, to be to be invited by the chair of the  
37           working group;
- 38
- 39           (11) A representative of the Hawaii Psychiatric Medical  
40           Association, to be invited by the chair of the working  
41           group; and



1 (12) A member of the public with executive or managerial  
 2 responsibilities for a medical cannabis dispensary  
 3 licensed under Chapter 329D, Hawaii Revised Statutes,  
 4 or a representative of the Hawaii Educational  
 5 Association for Licensed Therapeutic Healthcare, to be  
 6 appointed by the chair of the working group; and  
 7

8 BE IT FURTHER RESOLVED that the chair of the Medicinal  
 9 Psilocybin Working Group may invite other interested parties  
 10 with relevant experience to join the working group; and  
 11

12 BE IT FURTHER RESOLVED that the Medicinal Psilocybin  
 13 Working Group is requested to submit a preliminary report of its  
 14 findings and recommendations to the Legislature no later than  
 15 twenty days prior to the convening of the Regular Session of  
 16 2021, and a final report of its findings and recommendations,  
 17 including any proposed legislation, to the Legislature no later  
 18 than twenty days prior to the convening of the Regular Session  
 19 of 2022; and  
 20

21 BE IT FURTHER RESOLVED that the Medicinal Psilocybin  
 22 Working Group be dissolved on July 1, 2022; and  
 23

24 BE IT FURTHER RESOLVED that certified copies of this  
 25 Resolution be transmitted to the Director of Health, Attorney  
 26 General, Dean of the John A. Burns School of Medicine, and  
 27 chairs of the Senate and House of Representatives standing  
 28 committees whose subject matter purview is primarily responsible  
 29 for reviewing legislation relating to health and to the  
 30 Judiciary.  
 31  
 32  
 33

OFFERED BY:

MAR - 6 2020

